Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence - Quiz - MDSpire

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • By

  • Francesco D’Oria

  • Francesco Piscazzi

  • Paola Facheris

  • Giulio Foggi

  • Marco Ardigò

  • Antonio Costanzo

  • Mario Valenti

  • April 9, 2026

  • 0 min

Share

Original Source(s)

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • by Francesco D’Oria, Francesco Piscazzi, Paola Facheris, Giulio Foggi, Marco Ardigò, Antonio Costanzo, Mario Valenti

  • April 9, 2026

Related Content

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

UVB and Psoriasis: More Than Immunosuppression

UVB's benefits may run deeper than inflammation suppression—cholesterol metabolism could be a key link.